Screening for squamous cervical cancer: Duration of low risk after negative results of cervical cytology and its implication for screening policies: Iarc Working Group on Evaluation of Cervical Cancer Screening Programmes

British Medical Journal (Clinical research ed.)

Volumn 293, Issue 6548, 1986, Pages 659-664

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AGE; CANCER RISK; EPIDEMIOLOGY; FEMALE GENITAL SYSTEM; HUMAN; METHODOLOGY; POLICY; PREVENTION; PRIORITY JOURNAL; SCREENING; UTERINE CERVIX CYTOLOGY; VALUE;

ADULT; AGE FACTORS; CARCINOMA, SQUAMOUS CELL; CERVIX NEOPLASMS; FEMALE; GREAT BRITAIN; HEALTH POLICY; HUMAN; MASS SCREENING; MIDDLE AGE; RISK; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; VAGINAL SMEARS;

EID: 0022530903     PISSN: 02670623     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.293.6548.659     Document Type: Article

References (31)

1. Canadian Task Force. Cervical cancer screening programs, 1976. Can Med Assoc J 1976; 114: 1003-33.
2. Canadian Task Force. Cervical cancer screening programs: summary of the 1982 Canadian Task Force report. Can Med Assoc J 1982;127:581-9.
3. Department of Health and Social Security. Health services development: screening for cervical cancer. London: DHSS, 1984. (HC(84)17.)
4. NIH Consensus Statement. Cervical cancer screening: the Pap smear. Br Med J 1980;281:1264-6.
5. Macgregor JE, Baird D. Detection of cervical carcinoma in the general population. Br Med J 1963; i: 1631–6.
6. Macgregor JE. Evaluation of mass screening programmes for cervical cancer in NE Scotland. Turnon 1976;62:287-95.
7. Macgregor JE, Moss SM, Parkin DM, Day NE. A case-control study of cervical cancer screening in north east Scotland. Br Med J 1985;290:1543-6.
8. Fidler HK, Boyes DA, Worth AJ. Cervical cancer detection in British Columbia. A progress report. Journal of Obstetrics and Gynaecology of the British Commonwealth 1968;75:392-404.
9. Boyes DA, Morrison B, Knox EG, Draper GJ, Miller AB. A cohort study of cervical cancer screening in British Columbia. Clin Invest Med 1982;5:1-29.
10. Thorarinsson A, Jensson O, Bjarnason O. Screening for uterine cancer in Iceland. Acta Cytol 1969;13:302-8.
11. Johannesson G, Geirsson G, Day NE. The effect of mass screening in Iceland 1965–74 on the incidence and mortality of cervical carcinoma. Int J Cancer 1978;21:418-25.
12. Johannesson G, Geirsson G, Day NE, Tulinius H. Screening for cancer of the uterine cervix in Iceland—1965-1978. Acta Obstet Gynecol Scand 1982;61:199-203.
13. Choi NW, Nelson NA, Abu-Zeid HAH. Cervical cytology program and its effects on cervical cancer incidence and mortality by geographical areas in Manitoba. In: Nieburgs HE, ed. Prevention and detection of cancer. Vol 2, pt II. New York: Marcel Dekker, 1980:1891-907.
14. Berget A. Influence of population screening on morbidity and mortality of cancer of the uterine cervix in Maribo Amt. Dan Med Bull 1979; 26: 91-100.
15. Lynge E, Poll P. Incidence of cervical cancer following negative smear. A cohort study from Maribo county, Denmark. Am J Epidemiol (in press).
16. Berget A, Moller KA, Olsen J, Poll P. Rescreening for cervical carcinoma in Maribo Amt 1971–1975. Dan Med Bull 1978;25:232-4.
17. Norwegian Cancer Society. Mass screening for cancer of the uterine cervix in Ostfold county 1959–1965. Report No 1. Oslo: Norwegian Cancer Society, 1967.
18. Pedersen E, Hoeg K, Kolstad P. Mass screening for cancer of the uterine cervix in Ostfold county, Norway: an experiment. Second report of the Norwegian Cancer Society. Acta Obstet Gynecol Scand [Suppl] 11, 1971.
19. Hougen A. Mass screening for cancer of the uterine cervix in the county of Ostfold, Norway. In: Nieburgs HE, ed. Prevention and detection of cancer. New York: Marcel Dekker, 1980:1875-84.
20. Stenkvist B, Bergstrom R, Eklund G, Fox CH. Papanicolaou smear screening and cervical cancer. What can you expect? J Am Med Assoc 1984;252:1423-6.
21. Pettersson F, Bjorkholm E, Naslund I. Evaluation of the effect of Papanicolaou screening in Sweden. 2. Trends in incidence and mortality for cancer of the uterine cervix in Sweden 1958–1980. Int J Epidemiol (in press).
22. Raymond L, Obradovic M, Riotton G. Une étude cas-temoins pour 1'évaluation du depistage cytologique du cancer du col uterin. Rev Epidemiol Sante Publique 1984;32:10-5.
23. Berrino F, Gatta G, D'alto M, Crosignani P, Riboli E. Efficacy of screening in preventing invasive cervical cancer. A case-control study carried out in Milan, Italy. In: Hakama M, Miller AB, Day NE, eds. Screening for cervical cancer. Lyon: International Agency for Research on Cancer (in press). (IARC Scientific Publications, No 76.)
24. Clarke EA, Anderson TW. Does screening by “Pap” smears help prevent cervical cancer? A case-control study. Lancet 1979; ii: 1–4.
25. Hakama M, Day NE, Miller AB, eds. Screening for cervical cancer. Lyon: International Agency for Research on Cancer (in press). (IARC Scientific Publications, No 76.)
26. Day NE, Walter SD. Simplified models for screening: estimation procedures from mass screening programmes. Biometrics 1984;40:1-14.
27. Brookmeyer R, Day NE, Moss S. Case-control studies for the estimation of the natural history of preclinical disease from screening data. Stat Med 1985;5:127-38.
28. Storer BE, Wacholder S, Breslow NE. Maximum likelihood fitting of general relative risk models to stratified data. Applied Statistics 1983;32:172-81.
29. La Vecchia C, Franceschi S, Decarli A, Fasoli M, Gentile A, Tognoni G. “Pap” smear and the risk of cervical neoplasia: quantitative estimates from a case-control study. Lancet 1984; ii: 779-82.
30. Aristizabal N, Cuello C, Correa P, Collazos T, Haenszel W. The impact of vaginal cytology on cervical cancer risks in Cali, Colombia. Int J Cancer 1984;34:5-9.
31. Hakama M. Trends in the incidence of cervical cancer in the Nordic countries. In: Magnus K, ed. Trends in cancer incidence. Washington: Hemisphere, 1982:279-92.